Gail is the Vice President of Intellectual Property Strategy for Immunai. She oversees IP strategy for Immunai's partnerships and collaborations, as well as overseeing Immunai's growing IP portfolio of patents and trade secrets.
Prior to Immunai, Gail was the Vice President and Chief Intellectual Property Counsel of Envista Holdings Corporation (NYSE:NVST), overseeing the global IP portfolios and IP M&A strategy of one of the world’s largest dental companies, with $3 Billion of annual revenue on dental consumable, equipment and imaging products. Previously, Gail was Senior IP Counsel for Amgen (NASDAQ:AMGN), specializing in IP litigation. She began her career in private practice in NY and LA based law firms and clerking for the Court of Appeals for the Federal Circuit in Washington, DC. Gail holds a JD from Harvard Law School, and a BA in Chemistry from Columbia University.
Shany is a Human Resources executive with broad experience in global HR management at SaaS organizations & startups. With over 15 years of experience, she brings a successful track record in supporting robust company growth, implementing major changes through strong business-related strategy execution and building management teams. In-depth experience in initiating, executing and implementing HR strategies and solutions grounded in systems thinking, analytics and organizational effectiveness practices to increase productivity and employees’ engagement. Shany started at Panaya as the HR Business Partner of the global Sales and CS departments and was promoted to VP People on August 2018. Prior to Panaya Shany functioned as the Global VP HR of RealMatch, a Job Advertising platform, powered by AI. At RealMatch she led the HR department, building and shaping strong HR foundations, global multidisciplinary recruitment, maximizing the value of human capital, and aligning it with company initiatives, values and strategic objectives. Shany holds both a Bachelor degree in Human Resources and Sociology and a Master degree in Organizational Consulting and Development from Bar-Ilan University. After spending the last 10 years in the U.S., recently Shany and her family moved back to Israel.
Raviv Pryluk is the VP of Operations and the head of the target Discovery, Validation and Evaluation R&D group. Prior to joining Immunai, Raviv had a dual career in both the Israeli government and the academy. Raviv holds Ph.D. in computational neuroscience from the Weizmann institute (Magna Cum Laude, John F.Kennedy Prize winer) and MsC and BsC in engineering from the Technion, Israel Institute of technology both Cum Laude.Raviv also was a technological leader and commander in the Israel military Intelligence, and in his last role there he was a head of technological branch (Lieutenant colonel). During his service, Raviv won several prestigious prizes such as the Israel Prize for Technological Excellence and the IDI Prize for Creative Thinking.
Dhiren Belur is a seasoned leader with over 15 years of experience in the Diagnostics and Pharma industries developing and commercialising products that impacts the lives of Cancer Patients. Most recently he was at Guardant Health, a leader in comprehensive liquid biopsy, where he held various positions in marketing, and business development, including driving key parts of the companion diagnostics business. Prior to that, Dhiren was at Novartis where he helped build the high-throughout screening team.
Dhiren has an MBA from Berkeley, and a Masters in Bioengineering from UC San Diego. At Immunai, Dhiren drives strategic partnerships to enable drug discovery and development through the company’s single cell and ML-powered platform.
Jacques Banchereau is a research scientist with a 35-year track record of productivity in human immunology research and academic and industrial research leadership. At the Schering-Plough/ DNAX Laboratory fo Immunological Research in Lyon, France, he made significant contributions toward the discovery and characterization of numerous human cytokines, including IL4, IL-10, IL-13, IL-17, and GM-CSF; human B-cell biology, in particular B-cell growth, differentiation, and isotype switching; developing methods for in vitro generation of human dendritic cells (DCs); and functional characterization of various DC subsets.
At the Baylor Institute for Immunology Research in Dallas, Texas, Dr. Banchereau facilitated major advances in our understanding of human DC biology and the therapeutic use of DCs in cancer and infectious diseases. He also helped identify the role of type I interferon in systemic lupus erythematosus and IL-1 in systemic onset juvenile idiopathic arthritis, which led to the novel application of IL-1 antagonists as powerful therapeutics for juvenile arthritic disease. He also helped develop DC-based vaccines for use in a series of clinical trials for the treatment of metastatic melanoma, as well as for HIV infection. As director at both institutions, he secured domestic and international funding, including several NIH program projects and an Inserm unit supported by the French government. As chief scientific officer of Roche in Nutley, New Jersey, he oversaw the discovery and development unit (including phase IIB clinical trials) in the areas of virology and inflammation.
In his former role at The Jackson Laboratory (JAX) for Genomic Medicine in Farmington, Connecticut, Dr. Banchereau built a human immunology research program and ran an active laboratory focused on the genomics of immune function and human immune disease. Dr. Banchereau study the alternatively spliced junction of cancer isoforms as potential shared neoantigens using long-read sequencing. Other projects in the lab included epigenomic and isoform profiling to understand - the pediatric autoimmune diseases and responses to vaccination. Many of these studies heavily relied on the single cell RNA sequencing. During his career, Dr Banchereau has authored and co-authored >500 papers with 126,000 citations and an h-index of 159.
Dr. Banchereau is now the Chief Scientific Officer (CSO) at Immunai (New York).
Ethan Grant joined as VP, Therapeutics Discovery to lead Immunai’s effort to bring novel therapeutics into development for immuno-oncology and inflammatory disease indications. Prior to Immunai, Ethan held roles of increasing scope in pre-clinical drug discovery, translational medicine and clinical development at Gilead Sciences, MedImmune/AstraZeneca, Schering-Plough/Merck and Millennium Pharmaceuticals. He completed his Ph.D. and postdoctoral training in Immunology at Harvard University and holds a BA in Cell and Molecular Biology from Northwestern University.
Robert Langer serves on Immunai's Board of Directors. Bob was formerly the Germeshausen Professor of Chemical and Biomedical engineering and maintains activity in the Department of Chemical Engineering and the Department of Biological Engineering at Massachusetts Institute of Technology. Bob is also a faculty member of the Harvard-MIT Program in Health Sciences and Technology and the Koch Institute for Integrative Cancer Research.
Langer holds over 1,400 granted or pending patents and is one of the world's most highly cited researchers and his h-index is now 294 with currently over 353,000 citations. He is widely recognized in biotechnology, especially in the fields of drug delivery systems and tissue engineering. Bob is also a prolific entrepreneur and participated in the founding of over 40 biotechnology companies, including Moderna.
Langer's research laboratory at MIT is the largest biomedical engineering lab in the world; maintaining over $10 million in annual grants and over 100 researchers. He has been awarded numerous leading prizes in recognition of his work.
Caroline Uhler co-directs the Eric and Wendy Schmidt Center at the Broad Institute. She is also Associate Professor in the Department of Electrical Engineering and Computer Science and the Institute for Data, Systems, and Society at MIT.
Uhler develops machine learning methods for integrating and translating between vastly different data modalities and inferring causal or regulatory relationships from such data. She is particularly interested in using these methods to gain mechanistic insights into the link between genome packing and regulation in health and disease.
Uhler is recognized as a creative and innovative researcher at the intersection of machine learning, statistics, and biology. She has received multiple prestigious career prizes including a Simons Investigator Award, a Sloan Research Fellowship, a Sofja Kovalevskaja Award, and an NSF Career Award.
Uhler holds an M.Sc. in mathematics, a B.Sc. in biology, and an M.Ed., all from the University of Zurich. She obtained her Ph.D. in statistics from UC Berkeley in 2011 and then spent three years as an assistant professor at IST Austria before joining the faculty at MIT.
Dr. Stanley R. Frankel (M.D.) is Chief Medical Officer at Cytovia Therapeutics and Adjunct Professor of Medicine at the Division of Hematology/Oncology at Columbia University’s Vagelos College of Physicians and Surgeons, and Consultant to the world’s most innovative companies developing immuno-oncology and cellular therapies, drugs and compounds. Dr. Frankel sits on the Board of Directors and the Science and Technology Committee of Precision BioSciences, Inc. where he supports the development, approval and commercial deployment of advanced gene correction therapies.
Dr. Frankel is a leading academic and industry expert in the research, clinical development, and commercialization of cellular therapies. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies including acute lymphoblastic leukemia, multiple myeloma, and lymphoma.
Dr. Frankel has held the highest executive and leadership positions at Bristol-Myers Squibb (BMS), Celgene, Merck, AMGEN, Hoffmann-LA Roche, and others; he has also served on steering/development committees with JW Therapeutics, Jounce Therapeutics, Astra-Zeneca/Medimmune, Juno Therapeutics, and BeiGene.
Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University, and has been a board-certified licensed physician since 1986. He completed his residency at Mount Sinai Hospital and his fellowship at Memorial Sloan Kettering Cancer Center, where he was Chief Fellow. Frankel has held academic and clinical appointments at Roswell Park Cancer Institute, Georgetown University, and the University of Maryland.
Mark Jacobstein, our Chief Business Officer, came to Immunai by way of Guardant Health, where he spent four years as the Chief User Engagement Officer.
Prior to this Mark was CEO of iSkoot until its acquisition by Qualcomm. Mark was also an EVP at loopt (sold to GreenDot) and the co-founding President of Sequoia-backed Digital Chocolate, a pioneer in mobile games.
In 1994 Mark founded Small World Sports, the world's first online fantasy sports business, and served as CEO until he sold the business in 2002. Mark also co-founded Small World Software, which he sold to iXL, where he served as SVP of business development through their 1998 IPO.
Mark earned his BA from Harvard University, where he concentrated in Computer Science, and lives in Stanford, CA with his family.
Adeeb Rahman, Immunai's Senior Director of Single-Cell Immunology, joined Immunai after nearly a decade at the Icahn School of Medicine at Mount Sinai in a variety of roles.
Most recently, Adeeb was an Associate Professor in the Department of Genetics and Genomic Sciences, a member of the Precision Immunology Institute and Tisch Cancer Institute and served as the Director of Technology Development for the Human Immune Monitoring Center.
In that role, he led a team of wet bench and computational scientists focused on developing and optimizing high-dimensional cytometry and multi-modal single-cell immunological assays, and collaboratively applying them across a wide range of basic, translational and clinical research projects.
His lab also served as a central hub for several multi-institutional academic and industry collaborations including the NIH Human Immunology Project Consortium (HIPC), the CZI Seed Networks for the Human Cell Atlas (HCA), the NCI Cancer Immune Monitoring and Analysis Centers (CIMAC) and the Partnership for Accelerating Cancer Therapies (PACT).
Adeeb earned his Bachelor of Science in Biology from Brown University and his PhD in Immunology from the University of Pennsylvania School of Medicine and completed postdoctoral fellowships at the University of North Carolina, Chapel Hill and the Icahn School of Medicine at Mt. Sinai. He lives in New York City with his wife and two daughters.
Dr. Ye received his bachelor’s degrees in Electrical Engineering and Computer Sciences and Bioengineering from UC Berkeley and a PhD in Systems Biology from UC San Diego.
After a postdoctoral fellowship at the Broad Institute with Dr. Aviv Regev, Dr. Ye started his lab at UCSF five years ago. At UCSF, he is an Associate Professor in the Department of Medicine and is a member of the Institute for Human Genetics, the Bakar Institute for Computational Health Sciences and the Gladstone Institute for Genomic Immunology. He is also an affiliated investigator at the Parker Institute for Cancer Immunotheraphy and the Chan Zuckerberg Biohub.
The Ye lab is interested in understanding how genetic variants influence the transcriptional response of immune cells to their environment. The lab develops experimental and computational methods for the high-throughput single-cell measurement and analysis of gene expression across population cohorts, perturbational screens, and tissue regions.
These approaches are being used to study primary human immune cells in both healthy donors and disease patients to dissect gene regulatory mechanisms that underlie host pathogen interactions, the development of autoimmunity, and natural and acquired cancer immunity.
Dr. Littman is a Howard Hughes Medical Institute Investigator and the Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Professor of Pathology and Microbiology at the New York University (NYU) School of Medicine.
Dr. Littman is a Fellow of the American Academy of Arts and Sciences and is a Member of the National Academy of Sciences and of the National Academy of Medicine. He is recipient of the New York City Mayor’s Award for Excellence in Science and Technology, the AAI-Invitrogen Meritorious Career Award, the Ross Prize in Molecular Medicine, the William B. Coley Award from the Cancer Research Institute, and the Vilcek Prize in Biomedical Sciences.
Dr. Littman has made numerous groundbreaking discoveries in the fields of virology and immunology, including identification and isolation of receptors required for human immunodeficiency virus (HIV) entry, molecular mechanisms of immune cells that mediate autoimmunity and the role of specific members of the gut microbiota in T-cell differentiation.
Michael Kalos, PhD is an internationally recognized expert in T cell therapy and immunotherapy and brings over 25 years of experience and expertise in cell therapy, oncology vaccines, and immuno-oncology.
Most recently Dr. Kalos served as Executive Vice President and Head of R&D at ArsenalBio, a synthetic biology-based cell therapy start-up. At ArsenalBio Michael played a key role to develop the corporate R&D strategy and had direct remit to establish the product development organization and the strategy for the company’s first product.
Prior to ArsenalBio Dr. Kalos served as Vice President of Immunooncology and Oncology Cell Therapies at Janssen, the pharmaceutical companies of Johnson and Johnson, where he led corporate internal and external strategy and efforts in cell therapy, neoantigen vaccines, and immuno-oncology.
Prior to Janssen, Dr. Kalos served as Chief Scientific Officer of immuno-oncology at Eli Lilly and Company, where he established and led internal and external corporate strategy in immuno-oncology, including biologics, bi-specifics, vaccines, and cell therapy. Prior to joining the biopharmaceutical sector, Dr. Kalos spent 10 years in academia, where he focused on the development of integrated translational biomarker programs to support the development of cell therapy and immunotherapy programs. The laboratory he founded and directed at the University of Pennsylvania played a key role in the success of the cell therapy program at Penn, including clinical development of the CTL019 program that was licensed to Novartis and led to the approval of Kymriah.
Dr. Kalos obtained his PhD from the University of Minnesota and completed post-doctoral training in the laboratory of Phil Greenberg at the Fred Hutchinson Cancer Research Center.
Dr. Kalos has co-authored over 85 peer-reviewed manuscripts, including multiple highly cited articles in high-impact journals that have helped define the space of CAR- and TCR- based T cell therapy, as well as book chapters in the field of cancer immunotherapy, and has 26 issued patents in the field of cell therapy, immunotherapy, and vaccines. He actively serves and has served as an advisory member for biopharmaceutical companies, as well as international immunotherapy consortia and societies.
Dr. Rahul Satija is a Core Faculty Member at the New York Genome Center, with a joint appointment as an Associate Professor at the NYU Center for Genomics and Systems Biology.
Dr. Satija's group focuses on developing computational and experimental methods to sequence and interpret the molecular contents of a single cell. His group applies single cell genomics to understand the causes and consequences of cell-to-cell variation, with a particular focus on immune regulation and early development.
Dr. Satija holds a BS in Biology and Music from Duke University, and obtained his PhD in Statistics from Oxford University as a Rhodes Scholar. Prior to joining the New York Genome Center, he was a postdoctoral researcher at the BroadInstitute of Harvard and MIT, where he developed new methods for single cell analysis.
Kimary Kulig is passionate about the best interest and care of cancer patients. This includes application of artificial intelligence for more accurate diagnosis, minimized tissue-based biomarker testing, predicting response to therapy, and expediting the start of precise therapy.
Kimary’s oncology-focussed pharma career of over 11 years at both Pfizer and Bristol Myers Squibb spanned roles in Health Outcomes Research, Molecular Epidemiology, and Medical Affairs. Between these roles, Kimary served as Vice President of the Outcomes Research Database at the National Comprehensive Cancer Network(NCCN).
Kimary’s interest in computational and AI approaches to biomarker discovery and companion diagnostic development led her to Google and Verily Life Sciences. There, she formed a multi-disciplinary team to work on digital pathology image analysis algorithms to predict tumor biomarkers and response to treatment. Kimary continues in her goal to bring AI tools to clinical practice in affiliation with Path Presenter Corp. where she serves as Chief Strategy Officer. Kimary is Owner and Principal of Kulig Consulting, LLC, advising companies developing oncology products or services.
Kimary received her PhD from New York University’s Institute of Graduate Biomedical Sciences and her MPH from Columbia University’s Mailman School of Public Health.
Dr. Sam Funt, MD is a medical oncologist at Memorial Sloan Kettering Cancer Center and is focused on the discovery of more effective and personalized treatment strategies for patients with bladder cancer (urothelial carcinoma) and testicular cancer (germ cell tumors).
Dr. Funt is focused on defining biomarkers of response to standard and emerging therapies as well as the development of novel immunotherapy treatments for these diseases.
After being selected to join the faculty as a second-year chief medical oncology fellow, Dr. Funt has helped lead a significant expansion of Memorial Sloan Kettering’s clinical research program for immunotherapeutics; he is currently the principal investigator of multiple immunotherapy clinical trials and has led collaborative translational efforts to define the anti-tumor immune response with both academic and industry partners.
Dr. Leonid Metelitsa is a Professor at Baylor College of Medicine. His research is focused on understanding the role of Vα24-invariant Natural Killer T (iNKT) cells in tumor immunity and developing iNKT cell-based cancer immunotherapy.
He originally demonstrated that iNKT cells localize to primary tumors in humans and their presence at the tumor site is associated with favorable outcomes (Metelitsa et al., JEM, 2004). Metelitsa and his team then revealed the underlying mechanistic basis of iNKT cell tumor localization and function in the tumor microenvironment (Song et al., JCI, 2007; Song et al., JCI, 2009, Liu et al., JCI, 2012).
They also developed original technologies for iNKT cell isolation, genetic modification with chimeric antigen receptors (CAR), and expansion to clinical scale (Heczey et al., Blood, 2014; Tian et al., JCI, 2016, Ngai et al., JI, 2018).
The first clinical trials of autologous and allogeneic CAR-iNKT cells are currently ongoing in patients with neuroblastoma (Heczey et al., Nat Med, 2020) and B-cell malignancies, respectively while other iNKT cell-based therapeutics are at different stages of pre-clinical development.
Andras Heczey is a physician-scientist at Baylor College of Medicine and Texas Children's Hospital focused on the development of safe and effective therapies for patients with cancer using genetically engineered immune effectors.
His team is currently exploring the evolution of CAR T and CAR NKT cells post-infusion in patients using transcriptomic and cell surface marker assessment at the single-cell resolution.
His state-of-the-art analytical pipeline should provide exceptional insight into the changing functional states of therapeutic cells and identify immune escape mechanisms employed by the solid tumor microenvironment to guide the development of highly effective and specific countermeasures in the next generation of clinical studies.
Alexander Huang, MD is an Assistant Professor at Medicine at the Perelman School of Medicine, University of Pennsylvania.
Dr. Huang’s research program focuses on translational cancer immunology research, taking advantage of innovative clinical trials to 1) identify targets for novel immunotherapies in cancer, and 2) understand mechanisms of resistance.
Dr. Huang’s research involves the integration of immunotherapy trials, flow cytometric and transcriptional approaches, and advanced computational analysis to understand the underlying cellular mechanism of immunotherapies in the human system.
Specifically, he has a long-standing interest on the role of PD-1 blockade on CD8 T cell reinvigoration in human cancer, and defined the early pharmacodynamic immune response to PD-1 blockade in melanoma.
Dr. Regina Barzilay is a School of Engineering Distinguished Professor for AI and Health in the Department of Electrical Engineering and Computer Science and a member of the Computer Science and Artificial Intelligence Laboratory at the Massachusetts Institute of Technology. She is an AI faculty lead for Jameel Clinic, an MIT center for Machine Learning in Health.
Her research interests are in natural language processing and applications of deep learning to chemistry and oncology. She is a recipient of various awards including the NSF Career Award, the MIT Technology Review TR-35 Award, Microsoft Faculty Fellowship and several Best Paper Awards at NAACL and ACL. In 2017, she received a MacArthur fellowship, an ACL fellowship and an AAAI fellowship. In 2020, she was awarded the Squirrel AI Award for Artificial Intelligence for the Benefit of Humanity.
She received her PhD in Computer Science from Columbia University, and spent a year as a postdoc at Cornell University. Prof. Barzilay received her undergraduate degree from Ben-Gurion University of the Negev, Israel.
Dr. Matthew Hellmann received a BA from the University of Pennsylvania, MD from Johns Hopkins University, completed residency training in Internal Medicine at the Massachusetts General Hospital, and medical oncology fellowship training at Memorial Sloan Kettering Cancer Center.
Dr. Hellmann is now an Associate Attending at Memorial Sloan Kettering, specializing in the care of patients with lung cancers. His research focuses on identifying the predictors of response to immunotherapies and developing new ways to harness the body’s immune system to fight cancer.
Steven D. Averbuch, M.D. is an industry veteran with more than 35 years in oncology drug development, more than a decade in biomarker and drug diagnostic co-development, and has contributed to multiple drug and companion diagnostic approvals in the U.S. and other major markets.
During his tenure at Bristol-Myers Squibb, he spearheaded the Pharmacodiagnostics Center of Excellence, established in 2008, which led to the application of BMS’ precision medicine strategy across all therapeutic areas. Dr. Averbuch oversaw corporate-wide strategic initiatives for translational and targeted medicine and served as the Head of Early Global Clinical Research at Bristol-Myers Squibb, where he was responsible for early asset development strategy and execution of all Phase 2 oncology programs.
Dr. Averbuch served in leadership roles at Merck Research Laboratories for oncology clinical research and at AstraZeneca for oncology drug development.
Laurence Nore is a business executive with 20 years of experience in the US Life Sciences industry and a foundation in Banking in France, driving companies’ transformation. Her career spans a diverse set of companies including a drug discovery start up out of Stanford University, a pre-IPO molecular diagnostic company, the monoclonal antibody pioneer PDL Biopharma as well as iconic companies such as Amgen, Roche and Merck Millipore.
Laurence currently heads the Business and Commercial Development activities at Medicines360, building through partnerships a portfolio of marketed and pipeline treatments in women’s health. Prior to Medicines360, Laurence was on Globavir’s executive team where she pivoted the company from infectious diseases to immuno-oncology by redeploying its cheminformatics platform, creating new opportunities for partnerships and growth.
From 2011 to 2014 she led the strategy and execution of the new companion diagnostic business at Millipore, with the potential to increase revenues by $100M annually. Before joining Millipore, Laurence drove the transformation of Perlegen from a SNP-based biomarker discovery to a clinical diagnostic organization, by designing the commercial strategy and launching Brevagen™, a novel molecular test for the 32 million women at risk of developing breast cancer. While at PDL Biopharma she built market demand for 3 biologics transitioning into P3 trials, expanding the company beyond oncology and positioning it for commercial success.
In addition Laurence led the $100M acquisition of BioImagene by Roche Diagnostics, enabling the transition from routine to high-complexity testing with a new digital pathology platform. Earlier, while at Amgen, she completed the post merger financial integration of Tularik and managed the $100 Million budget of the new 300-people site, deploying capital and people to grow the small molecule pipeline.
Laurence Nore is an independent board member of a French VC-backed diagnostic company, as well as an angel investor with Astia. She earned an MBA from the Anderson School at UCLA and a BA equivalent in Corporate Finance from Ecole de Management de Lyon (France).
Dr. Marton serves as a consultant to industry and to nonprofit, government, and academic institutions. In the nonprofit sector, Dr. Marton serves on the Board of Trustees of the American Association for Cancer Research Foundation and on the Board of Directors of Cancer Commons.
In the for-profit sector, he serves on the Board of Directors of Cellsonics, Dategra, Matternet, Microsonic Systems, Nanotics, Omniox (also serving as Executive Chair), RenovoRx, and xCures; is Chair of the Scientific Advisory Board of PharmaJet; is an advisor to Assurance Health Data, Ciitizen, Enable Medicine, Immunai, and the Precision Medicine World Conference; and is on the Editorial Board of the Journal of Precision Medicine.
Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. Dr. Marton received his MD from the Albert Einstein College of Medicine.
Michael Aberman, M.D. is a biotechnology executive with over 20-years experience who is on the board or advising several early stage biotechnology companies.
Previously, he was the president and chief executive officer of Quentis Therapeutics, an early stage biotech company. Prior to joining Quentis, Dr. Aberman spent over seven years at Regeneron Pharmaceuticals as the Senior Vice President of Investor Relations and Strategy. In that role, Dr. Aberman was a member of the senior management team and was responsible for the investor relations, corporate communications, business development, and corporate strategy functions at Regeneron.
Prior to joining Regeneron, Dr. Aberman spent six years as a Wall Street research analyst covering the biotechnology industry at Credit Suisse and Morgan Stanley.
Before moving to Wall Street, Dr. Aberman was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company.
Dr. Aberman received B.A. from Cornell University (’93), his medical degree from the University of Toronto (’97), completed residency training at New York Presbyterian Hospital, and received an M.B.A. from The Wharton School of Business (’01).
Sen Zhang, Immunai’s Vice President of Product, joined Immunai in January 2020 as its first product hire.
Prior to Immunai, Sen spent a decade leading a variety of product and business initiatives at Two Sigma Investments, Flatiron Health, and Palantir Technologies. Sen started his career as a consultant at Oliver Wyman, working on a variety of projects in the financial services industry.
Sen earned BAs in Biology and Economics at Dartmouth College. He lives in New York City with his wife.
Tali Raveh-Sadka, Immunai’s Senior Director of Computational Biology, holds a PhD in Computational Biology from the Weizmann Institute of Science and completed her post doc at the University of California, Berkeley. Prior to joining Immunai, Tali was the Director of Research at DayTwo.
Tali lives in Israel with her husband, father-in-law, two kids, and three hamsters.
Noam Solomon is the CEO and co-founder at Immunai, the first company set to reprogram the immune system for better detection, diagnosis, and treatment of disease, and discovery of novel therapeutics.
Prior to co-founding Immunai, Noam had a dual career in both the industry and academia. Noam has a double Ph.D., in Math and Computer Science and served as a post-doctoral researcher in the Mathematics department at the Massachusetts Institute of Technology, and in the Center of Mathematical Sciences and Applications at Harvard University.
Noam also worked as an algorithms developer and a data scientist, consultant, and head of data science in several hi-tech companies in Israel.
Luis Voloch is the Chief Technology Officer and Co-Founder at Immunai, where he and the Immunai team are helping bring transformational change to immunology, cancer, science, and beyond by leveraging cutting edge AI, software, immunology, computational biology, and genomics technologies to fully map and reprogram the immune system.
Before co-founding Immunai, Luis served as Head of Data Science and Machine Learning and worked on a variety of Machine Learning efforts at Palantir and other companies, where he has worked on and led various AI, genomics, and software efforts.
Luis studied at the Massachusetts Institute of Technology for his BS in Mathematics and Computer Science and his Masters in Electrical Engineering and Computer Science, and won the prestigious Best Thesis award among all PhD-track students at the Massachusetts Institute of Technology’s Electrical Engineering and Computer Science department before leaving to industry.
Danny Wells is a scientific co-founder at Immunai and currently serves as the Senior Vice President of Strategic Research. Danny joined the founding team of Immunai during his time as an investigator at the Parker Institute for Cancer Immunotherapy, where he was the founding principal data scientist and led research efforts in genomics and reverse translational medicine.
Danny has co-authored dozens of research articles around the intersection of (single-cell) genomics and cancer immunotherapy that have collectively been cited thousands of times, including papers published in Nature, Cell, and Nature Medicine.
Before joining the Parker Institute, Danny completed a postdoctoral fellowship in evolutionary biology at the University of California, Berkeley, his PhD in Computational Biology and Applied Mathematics at Northwestern University, where he was an NSF Graduate Research Fellow, and a BA in Mathematics from Carleton College where received the Galovich Prize for accomplishment in undergraduate mathematics research.
Danny lives in Berkeley, CA with his wife and son, and enjoys spending time with them cooking and hiking in the hills around their home.
Dr. Ansuman Satpathy M.D., Ph.D. is an Assistant Professor in the Department of Pathology at Stanford University School of Medicine and a Scientific Co-Founder at Immunai. He is a member of the Stanford Cancer Institute, the Parker Institute for Cancer Immunotherapy, the Immunology, Cancer Biology, and Biomedical Informatics Programs, Bio-X, and a faculty fellow in ChEM-H.
Dr. Satpathy completed an M.D. and Ph.D. in immunology at Washington University in St. Louis, clinical residency in pathology at Stanford Hospital and Clinics, and postdoctoral training in genetics at Stanford University.
Dr. Satpathy’s research group focuses on developing and applying genome-scale technologies to study fundamental properties of the immune system in health, infection, and cancer.
Dr. Satpathy lives in San Mateo, CA with his wife and two girls.
Immunai was founded in December 2018. We are a multidisciplinary team of immunologists, genomics technologists, computer scientists, engineers, mathematicians and operators singularly focused on solving an audacious challenge. Backed by some of the leading scientific minds in immunology, oncology, and single cell genomics, we are up for the challenge.
Our team spans New York City, Tel Aviv, San Francisco, Prague, and Zurich.
We are excited to explore strategic partnerships with academic research institutions, biopharmaceutical companies, and biotechs to expand the use of our technology and data platform to unlock biological insights, advance novel therapeutic discovery, and accelerate R&D.Contact Us